Close

Minretumomab (TAB-249)

DESCRIPTION CATALOG # SIZE PRICE
Anti-Human TAG-72 Recombinant Antibody TAB-249 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant monoclonal antibody to tagged-72. Minretumomab is a mouse monoclonal antibody designed for the treatment of cancer.
  • Target
  • tagged-72
  • Type
  • IgG1
  • Immunogen
  • Membrane enriched fraction of a human breast carcinoma liver metastasis.
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in WB, FuncS, IF, Neut, ELISA, FC, IP and most other immunological methods.
  • CAS
  • 195189-17-4
  • Specific Activity
  • Tested positive against native human antigen.
  • Protein Construction
  • Immunoglobulin G1, anti-(human tumor-associated glycoprotein 72) (mouse monoclonal Mab CC49 g1-chain) disulfide with mouse monoclonal Mab CC49 k-chain, dimer
  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
  • Size
  • 1mg
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

BACKGROUND

  • Introduction
  • Mouse monoclonal antibody designed for the treatment of cancer.
  • Antigen Description
  • Tumor-associated glycoprotein 72 (tagged-72) is a glycoprotein found on the surface of many cancer cells, including ovary, breast, colon, and pancreatic cells. It is a mucin -like molecule with a molar mass of over 1000 kDa.
  • Keywords
  • CA 72.4; TAG 72; Tumor associated Glycoprotein 72

Related Products

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us